Payment overview · 2025
General Payments
$115.00
7 reported records · 5 companies
Healthcare provider profile · identity verified
Craig Alan Concannon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BELOIT, KS · NPI 1891764676
Verified facts
What the public records show
CMS Open Payments records show Craig Alan Concannon, M.D. received $115.00 in general payments during 2025 across 7 reported records.
Novartis Pharmaceuticals Corporation accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 441 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.43 | 36.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.56 | 26.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.11 | 13.1% | 1 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $14.06 | 12.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.84 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.00 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.43 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| ACUSON Sequoia Diagnostic Ultrasound System Normalized: acuson sequoia diagnostic ultrasound system |
Device | Siemens Medical Solutions USA, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 359 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
359 | 52 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
147 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
441 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 1150 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 827 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 769 | 131 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 768 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 692 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 603 | 101 |
| Furosemide | Furosemide | 569 | 101 |
| Gabapentin | Gabapentin | 502 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 490 | 80 |
| Eliquis | Apixaban | 441 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 387 | 68 |
| Carvedilol | Carvedilol | 376 | 56 |
| Lisinopril | Lisinopril | 369 | 67 |
| Jardiance | Empagliflozin | 359 | 52 |
| Spironolactone | Spironolactone | 336 | 63 |
| Omeprazole | Omeprazole | 330 | 54 |
| Allopurinol | Allopurinol | 305 | 49 |
| Losartan Potassium | Losartan Potassium | 299 | 66 |
| Simvastatin | Simvastatin | 284 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 37 |
| Metformin Hcl | Metformin Hcl | 252 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 49 |
| Atenolol | Atenolol | 231 | 38 |
| Donepezil Hcl | Donepezil Hcl | 229 | 32 |
| Xarelto | Rivaroxaban | 182 | 23 |
| Sertraline Hcl | Sertraline Hcl | 177 | 35 |
| Trazodone Hcl | Trazodone Hcl | 175 | 28 |
| Prednisone | Prednisone | 162 | 44 |
| Mirtazapine | Mirtazapine | 160 | 19 |
| Montelukast Sodium | Montelukast Sodium | 159 | 21 |
| Famotidine | Famotidine | 156 | 24 |
| Digoxin | Digoxin | 154 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 154 | 22 |
| Finasteride | Finasteride | 151 | 22 |
| Tramadol Hcl | Tramadol Hcl | 151 | 31 |
| Entresto | Sacubitril/Valsartan | 147 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 146 | 19 |
| Memantine Hcl | Memantine Hcl | 143 | 20 |
| Alprazolam | Alprazolam | 126 | 18 |
| Clonazepam | Clonazepam | 120 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 120 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 21 |
| Levetiracetam | Levetiracetam | 108 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 13 |
| Meloxicam | Meloxicam | 99 | 20 |
| Enalapril Maleate | Enalapril Maleate | 97 | 18 |
| Labetalol Hcl | Labetalol Hcl | 97 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 95 | 14 |
| Propranolol Hcl | Propranolol Hcl | 95 | 11 |
| Farxiga | Dapagliflozin Propanediol | 93 | 21 |
| Januvia | Sitagliptin Phosphate | 90 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 88 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 12 |
| Lorazepam | Lorazepam | 85 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | suppressed |
| Azithromycin | Azithromycin | 76 | 64 |
| Methylprednisolone | Methylprednisolone | 76 | 60 |
| Nifedipine Er | Nifedipine | 76 | 18 |
| Warfarin Sodium | Warfarin Sodium | 74 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 72 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 18 |
| Clonidine Hcl | Clonidine Hcl | 64 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 13 |
| Ezetimibe | Ezetimibe | 59 | suppressed |
| Levofloxacin | Levofloxacin | 59 | 46 |
| Ozempic | Semaglutide | 59 | suppressed |
| Budesonide | Budesonide | 57 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 56 | suppressed |
| Pregabalin | Pregabalin | 56 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 41 |
| Metformin Hcl Er | Metformin Hcl | 50 | 12 |
| Amoxicillin | Amoxicillin | 49 | 40 |
| Sucralfate | Sucralfate | 49 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 35 |
| Bumetanide | Bumetanide | 48 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Primidone | Primidone | 47 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 47 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Fentanyl | Fentanyl | 42 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 37 |
| Memantine Hcl Er | Memantine Hcl | 38 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 37 | 11 |
| Estradiol | Estradiol | 37 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 35 | 18 |
| Zonisamide | Zonisamide | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Colchicine | Colchicine | 34 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Roflumilast | Roflumilast | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 17 |
| Pentoxifylline | Pentoxifylline | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Nystatin | Nystatin | 31 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 30 | 11 |
| Levalbuterol Hcl | Levalbuterol Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 11 |
| Cephalexin | Cephalexin | 28 | 18 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Nystop | Nystatin | 19 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 16 |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Probenecid | Probenecid | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.00 · 7 records | Novartis Pharmaceuticals Corporation | ABRYSVO, ACUSON Sequoia Diagnostic Ultrasound System, EVENITY, JARDIANCE, LEQVIO, PREVNAR 20 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error